Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Presentation by Marc Rogers (Metrion CSO) at the 8th February 2018 SR Live event during Metrion’s 2018 Syndicate Room finance round.
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.